Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal

BACKGROUND: The 2014 West African outbreak of Ebola virus disease highlighted the urgent need to develop an effective Ebola vaccine. METHODS: We undertook 2 phase 1 studies assessing safety and immunogenicity of the viral vector modified vaccinia Ankara virus vectored Ebola Zaire vaccine (MVA-EBO-Z)...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Infect Dis
Autors principals: Venkatraman, Navin, Ndiaye, Birahim Pierre, Bowyer, Georgina, Wade, Djibril, Sridhar, Saranya, Wright, Daniel, Powlson, Jonathan, Ndiaye, Ibrahima, Dièye, Siry, Thompson, Craig, Bakhoum, Momar, Morter, Richard, Capone, Stefania, Del Sorbo, Mariarosaria, Jamieson, Sophie, Rampling, Tommy, Datoo, Mehreen, Roberts, Rachel, Poulton, Ian, Griffiths, Oliver, Ballou, W Ripley, Roman, François, Lewis, David J M, Lawrie, Alison, Imoukhuede, Egeruan, Gilbert, Sarah C, Dieye, Tandakha N, Ewer, Katie J, Mboup, Souleymane, Hill, Adrian V S
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2019
Matèries:
Major Articles and Brief Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6452431/
https://ncbi.nlm.nih.gov/pubmed/30407513
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/infdis/jiy639
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars